Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascendis Pharma A (ASND) Goodwill (2016 - 2022)

Historic Goodwill for Ascendis Pharma A (ASND) over the last 8 years, with Q4 2022 value amounting to $4.9 million.

  • Ascendis Pharma A's Goodwill fell 1832.63% to $4.9 million in Q4 2022 from the same period last year, while for Dec 2022 it was $4.9 million, marking a year-over-year decrease of 1832.63%. This contributed to the annual value of $4.9 million for FY2022, which is 1832.63% down from last year.
  • Latest data reveals that Ascendis Pharma A reported Goodwill of $4.9 million as of Q4 2022, which was down 1832.63% from $6.0 million recorded in Q4 2021.
  • Ascendis Pharma A's 5-year Goodwill high stood at $6.8 million for Q4 2020, and its period low was $3.9 million during Q4 2019.
  • Moreover, its 5-year median value for Goodwill was $4.9 million (2022), whereas its average is $5.1 million.
  • In the last 5 years, Ascendis Pharma A's Goodwill soared by 7619.73% in 2020 and then plummeted by 1832.63% in 2022.
  • Quarter analysis of 5 years shows Ascendis Pharma A's Goodwill stood at $4.0 million in 2018, then decreased by 3.02% to $3.9 million in 2019, then surged by 76.2% to $6.8 million in 2020, then fell by 11.52% to $6.0 million in 2021, then decreased by 18.33% to $4.9 million in 2022.
  • Its Goodwill stands at $4.9 million for Q4 2022, versus $6.0 million for Q4 2021 and $6.8 million for Q4 2020.